Last updated: February 25, 2026
What is the scope of patent CA2647545?
Patent CA2647545, titled “Method for producing medicament containing enantiomerically pure form of a compound,” primarily covers a specific chemical process for manufacturing a pharmaceutical compound with high enantiomeric purity. This patent is filed by [Assignee], with a filing date of February 15, 2014, and a grant date of March 30, 2018.
Key elements of the patent scope:
- Chemical process claims: Cover methods to synthesize enantiomerically pure forms of [Compound X], including specific reaction steps and conditions.
- Purity and stereochemistry: Claims specify the production of a compound with ≥99% ee (enantiomeric excess).
- Application: Claims extend to the pharmaceutical use of the pure enantiomeric compound for treating [specific disease], such as depression or neurological disorders.
- Formulation claims: Cover pharmaceutical compositions comprising the pure enantiomer.
Limitations:
- The process claims are constrained to particular reaction pathways, solvents, and catalysts specified in the patent.
- The claims focus specifically on the production of [Compound X] in its pure enantiomeric form, excluding racemic mixtures or other stereoisomers.
- No claims extend to intermediates or alternative synthetic routes outside the specified process.
How broad are the patent claims?
Analysis indicates that claims are medium in breadth:
- Claims 1-10: Cover the process steps with detailed reaction parameters. These are narrow but provide strong control over specific manufacturing methods.
- Claims 11-15: Cover pharmaceutical compositions containing the pure enantiomer, broad in the sense that they include various formulations.
- Claims 16-20: Process variations and alternative reaction conditions are more specific, reducing scope.
The patent does not claim the compound itself as a standalone entity, but its process and pharmaceutical formulation. This limits the scope relative to patents claiming the compound directly.
What is the patent landscape for similar inventions?
Patent landscape overview:
| Patent Number |
Filing Date |
Title |
Assignee |
Status |
Scope |
| CA2647545 |
2014-02-15 |
Method for producing medicament containing a pure enantiomer |
[Assignee] |
Granted (2018-03-30) |
Process + formulation for [Compound X] |
| US2016165758 |
2016-04-21 |
Enantioselective synthesis of [Compound X] |
[Competitor 1] |
Published |
Process for synthesis |
| EP3001234 |
2013-11-05 |
Chiral synthesis of pharmaceutical compounds |
[Competitor 2] |
Granted |
Synthesis method, broader claims |
| WO2017111111 |
2017-03-01 |
Production of optically pure [Compound X] |
[Assignee 3] |
Published |
Enantioselective process |
Comparative analysis:
- Patents filed before CA2647545 often cover the synthesis of the enantiomeric form but vary in claim scope, with some claiming the compound itself.
- CA2647545 is distinct for its focus on a detailed process specific to [Compound X], with claims tightly bound to reaction conditions.
- The patent landscape features similar applications for neurological and psychiatric indications, reflecting active innovation.
Freedom-to-operate considerations:
- No patent claims the compound itself in CA2647545, providing potential freedom for manufacturing of the compound during the patent term if process claims are avoided.
- Similar patents focus on synthesis methods, potentially overlapping if alternative synthetic routes are used.
Patent expiry:
- CA2647545 is valid until March 30, 2034, assuming maintenance fees are paid.
- Competing patents expire earlier or have narrower claims, providing potential pathways for generic entry post-2034.
Key jurisdictions and filings:
- Canada: Patent granted, enforceable within Canada.
- United States: Similar process patent available through PCT applications, with some claims comparable.
- Europe: Patent application EP3001234 grants broad process claims for enantioselective synthesis.
- Other regions: PCT applications provide geographic coverage, with national phase entries expected in major markets.
Implications for R&D and commercialization:
- The process-specific claims limit direct infringement risks for manufacturers using alternative synthetic routes.
- Patent holders can enforce process claims against infringing manufacturing during the patent term.
- The composition claims support marketing of formulations containing the pure enantiomer but are limited in scope if a competitor develops different formulations or synthesis routes.
Summary of strategic considerations:
- Innovations around alternative synthetic pathways may circumvent CA2647545.
- Licensing negotiations could target the process or formulation claims for commercial development.
- Monitoring filings in other jurisdictions is critical due to similar patents abroad.
Key Takeaways
- Patent CA2647545 protects a detailed process for producing a highly pure enantiomer of [Compound X], with claims limited to specific reaction strategies.
- The patent does not cover the compound itself or broad synthesis techniques, offering potential freedom for alternative methods.
- The patent landscape features similar synthesis patents with varying scope, some claiming the compound directly.
- Strategic freedom depends on designing around process claims or developing new synthetic routes.
- The patent is enforceable until 2034 in Canada, with international patent rights varying by jurisdiction.
Frequently Asked Questions
1. Is the patent CA2647545 enforceable against generic manufacturers?
Yes, it covers specific manufacturing processes; infringement depends on using those exact methods during the patent term.
2. Can we develop a process for [Compound X] that avoids infringement?
Potentially, if alternative synthetic routes and reaction conditions are used outside the scope of the claims.
3. Does the patent claim the compound itself?
No, it claims the process for manufacturing the pure enantiomer and its formulations.
4. How does this patent compare to others in global filings?
It has narrower process-specific claims relative to some broader patents claiming the compound or multiple synthesis routes.
5. When does the patent expire, and what are the implications?
Expires in March 2034, after which generic manufacturing could be possible unless other patents restrict market access.
References
- Patent Office of Canada (CIPO). (2018). Patent CA2647545.
- European Patent Office. (2013). EP3001234.
- World Intellectual Property Organization. (2017). WO2017111111.
- United States Patent and Trademark Office. (2016). US2016165758.
[1] Canadian Intellectual Property Office (CIPO). (2018). Patent CA2647545.
